GlassScriptPhysician profile
Sean S Bahri
NPI 1821273137
$3,311.61
in general payments reported to CMS, 2019-2025
14 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $119 · 2021: $12.24 · 2022: $399 · 2023: $275 · 2024: $892 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $871.57 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $595.15 | 2022-2025 | Tryptyr, Voyager Dslt, Hydrus Microstent |
| Allergan, INC. | $369.37 | 2019-2022 | |
| Amgen INC. | $277.65 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $236.65 | 2019 | |
| Harrow Eye, LLC | $164.06 | 2024 | Vevye |
| Abbvie INC. | $154.45 | 2023-2025 | Lumigan, Alphagan P |
| Oyster Point Pharma, INC. | $121.87 | 2023 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $118.01 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $116.68 | 2019 | |
| Apellis Pharmaceuticals, INC. | $114.73 | 2025 | Syfovre |
| Carl Zeiss Meditec, INC. | $95.00 | 2019 | |
| Astellas Pharma US INC | $64.18 | 2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Bahri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.